Colibri Transcatheter Aortic Heart Valve System Study
A legfontosabb adatok
- Ki végzi
- Colibri Heart Valve LLC
- Hol
- Egyesült Királyság és Franciaország5 helyszín, 2 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 30 fő, tervezett
- Kezdés
- 2021. szept. 15.
- Várható befejezés
- 2028. júl.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Colibri TAVI System
- A regiszteradat frissítve
- 2023. február 21.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for people over 75 years with severe aortic valve narrowing that causes symptoms, who are at high risk with open-heart surgery. They will get the Colibri valve through a leg artery.
- Életkor
- Over 75 years
- Nem
- All sexes can join
- A betegség stádiuma
- Severe narrowing of a three-leaflet aortic valve (mean pressure gradient > 40 mmHg or peak velocity > 4.0 m/s), with symptoms of NYHA > Class II. The local Heart Team must agree surgery risk is high. Aortic ring size > 22 mm and < 27.4 mm on CT scan. A central review committee must approve each person.
- Korábbi kezelés
- People who already had a heart valve implanted in any position cannot join.
A részvétel fő kizáró okai
- Leg and pelvic arteries too narrow or unfit for the valve to be passed through
- Aortic valve with one or two leaflets, or a valve problem present from birth
- Very weak heart pumping (LVEF < 30%) or severe leaking of other heart valves
- Recent heart attack (less than 30 days) or stroke or TIA (less than 6 months)
- Kidney failure needing chronic dialysis or creatinine clearance < 20cc/min
A regiszter feltételei, szó szerint
Mind a 40 feltétel megnézéseKevesebb
Ki vehet részt
- 1. Subject of age > 75 years
- 2. Subject suffering from severe aortic tricuspid valve stenosis defined as follows: High-gradient aortic stenosis (mean pressure gradient across aortic valve > 40 mmHg or peak velocity > 4.0 m/s)
- 3. Subject has symptomatic aortic valve stenosis with New York Heart Association (NYHA) > Class II
- 4. Subject with a documented local Heart Team (HT) agreement of high surgical risk as described in the population
- 5. ECG-gated Multi-Slice Computed Tomographic (MSCT) measurements determined an aortic annulus > 22 mm and < 27.4 mm
- 6. Subject deemed eligible by a TAVI Centralized Case Review Committee (CRC)
- 7. Subject can understand the purpose of the clinical investigation, has signed voluntarily the informed consent form and is agreeing to the scheduled follow-up requirements
Ki nem vehet részt
- 5. Previous implantation of heart valve in any position
- 17. Evidence of acute myocardial infarction (MI) less than 30 days before signing informed consent
- 18. Any need for emergency surgery
- 20. Symptomatic carotid or vertebral artery disease or successful treatment of carotid stenosis < 30 days prior to signing informed consent
- 29. Currently participating in another drug or device trial (excluding observational registries) for which the primary endpoint has not been assessed
- 31. For females, pregnancy or intention to become pregnant prior to completion of all follow-up procedures
- 2. Aortic root anatomy condition or lesion preventing implantation or access to the aortic valve
- 11. Multi-vessel coronary artery disease (CAD) with a Syntax Score or residual Syntax Score > 22 and/or unprotected left main coronary artery
- 13. Untreated cardiac conduction disease in need of pacemaker implantation
- 14. Uncontrolled atrial fibrillation (resting heart rate (HR) > 120bpm)
- 21. Any active bleeding that precludes anticoagulation
- 22. Liver failure (Child-C)
- 24. Pulmonary hypertension (systolic pressure >80mmHg)
- 25. Severe Chronic Obstructive Pulmonary Disease (COPD) demonstrated by a Forced Expiratory Volume (FEV1) < 750cc
- 28. Any medical, social or psychological condition that in the opinion of the investigator precludes the subject from giving appropriate consent or adherence to the required follow-up procedures
- 9. Severe left ventricular dysfunction (Left Ventricular Ejection Fraction (LVEF) < 30%)
- 16. Blood dyscrasias defined as: leukopenia (White Blood Cells (WBC) < 1,000/mm3), thrombocytopenia (Platelets (PLT) < 50,000/mm3), history of bleeding diathesis or coagulopathy, or hypercoagulable states
- 23. End-stage renal disease requiring chronic dialysis or creatinine clearance < 20cc/min
- 27. A known hypersensitivity or contraindication to all anticoagulation/anti-platelet regimens (or inability to be anticoagulated for the index procedure), to cobalt chromium, to porcine and/or collagen, to glutaraldehyde or contrast media
- 1. Arterial aorto-iliac-femoral axis unsuitable for transfemoral access as assessed by conventional angiography and/or multidetector computed tomographic angiography (access vessel diameter incompatible with a 16F sheath introducer)
- 3. Non-calcific acquired aortic stenosis
- 4. Native unicuspid/bicuspid aortic valve or congenital aortic valve abnormality
- 6. Severe aortic regurgitation (> 3+)
- 7. Severe mitral regurgitation (> 3+)
- 8. Severe tricuspid regurgitation (> 3+)
- 10. Echocardiographic evidence of intracardiac mass, thrombus or vegetation
- 12. Cardiogenic shock
- 15. Active and/or suspicion of endocarditis or ongoing sepsis
- 19. Recent (< 6 months of signing informed consent) CerebroVascular Accident (CVA) or Transient Ischemic Attack (TIA)
- 26. Refusal of blood transfusion
- 30. Estimated life expectancy of less than 12 months
- 32. Inability to comply with the clinical investigation requirements
- 33. Subject under judicial protection, tutorship or curatorship (for France only)
Ez a vizsgálat jelenleg itt érhető el: Egyesült Királyság és Franciaország.
2 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The Colibri Heart Valve clinical investigation ("COL-01") is a prospective, multicenter, exploratory single arm and controlled clinical investigation compared to recent historical results. This study will be conducted in about 7 European sites. The study will evaluate the safety and performance of the Colibri Transcatheter Aortic Heart Valve System for the treatment of symptomatic severe aortic stenosis via transfemoral access in high surgical risk patients.
A teljes eredeti leírásKevesebb
30 subjects suffering from symptomatic severe aortic tricuspid valve stenosis and who are at high surgical risk (logistic EuroSCORE I > 20% or other risk factors not included in this score such as frailty, porcelain aorta, sequelae of chest radiation or logistic EuroSCORE I < 20% but considered at high risk by local Heart Team evaluation) will be enrolled in this clinical investigation.
The primary objective of this clinical investigation is to evaluate the all-cause mortality at 30 days post implantation. The secondary objectives are to evaluate the safety and performance of the investigational device at 30 days, 6 and 12 months, and 2, 3, 4, 5 years post implantation.
A vizsgálat csoportja
- Colibri DeviceA vizsgált kezelés
Treatment
Kezelés: Colibri TAVI System
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Prospective, Single Arm Clinical Investigation Evaluating Safety and Performance of the Colibri Transcatheter Aortic Heart Valve System for the Treatment of Symptomatic Severe Aortic Stenosis Via Transfemoral Access in High Surgical Risk Patients
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2023. február 21.